«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

25卷

期数:

2019年05期

页码:

526-530

栏目:

Meta分析

出版日期:

2019-09-20

文章信息/Info

Title:

A meta-analysis on renal safety of tenofovirdisoproxil and entecavir in patients with chronic hepatitis B

文章编号:

1006-8147(2019)05-0526-05

作者:

苏 培¹; 2; 高卫真¹

（1.天津医科大学基础医学院药理学系，天津300070；2.天津市第三中心医院分院，天津300250）

Author(s):

SU Pei¹; 2;  GAO Wei-Zhen¹

（1.Department of Pharmacology, School of Basic Medical Sciences llege, Tianjin Medical University, Tianjin 300070, China; 2.Tianjin Third Hospital Branch, Tianjin 300250, China）

关键词:

替诺福韦酯; 恩替卡韦; 慢性乙型肝炎; 肾功能; Meta分析

Keywords:

tenofovirdisoproxil;  entecavir;  chronic hepatitis B;  renal function;  Meta-analysis

分类号:

R512.6+2

DOI:

-

文献标志码:

A

摘要:

目的：通过系统综述和Meta分析比较替诺福韦酯（TDF）与恩替卡韦（ETV）治疗慢性乙型肝炎（CHB）时，对肾功能包括肾小球滤过率（eGFR）、血肌酐(creatinine)、血磷酸盐（phosphate）的影响。方法：计算机检索PubMed、EMbase、Springer、Cochrane Library、中国期刊全文数据库、万方数据库2018年6月之前的有关TDF和ETV治疗CHB患者相关文献。按照NOS评分标准，评价纳入文章质量，采用Stata12.0进行Meta分析。结果：共纳入相关文献9篇，包括2 346例患者。Meta分析结果显示TDF和ETV在治疗CHB患者24月时，eGFR、血肌酐、血磷的SMD分别为-0.07（95%CI：-0.31~0.16），-0.15（95%CI：-0.46~0.17），-0.37（95%CI：-0.66~-0.08），组间效应24月时eGFR、血肌酐、血磷的影响分别是（t=2.48，P=0.056），（t=-1.98，P=0.105），（t=1.41，P=0.252）。结论：TDF和ETV在CHB患者治疗时，均影响肾功能，对eGFR、血肌酐、血磷的影响均无显著性差异。TDF和ETV治疗慢性乙型肝炎患者的肾安全有相似性。

Abstract:

Objective: To compare the effects on renal function including glomerular filtration rate（eGFR）, serumcreatinine and serum phosphate of tenofovirdisoproxil（TDF） and entecavir（ETV） in patients with chronic hepatitis B（CHB）. Methods: Various controlled study data before June 2018 through computer research were retrieved from PubMed, EMbase, Springer, Cochrane Library, CNKI, WanFang database for TDF and TEV effect on renal function when treating CHB patients. The quality of the included articles were assessed according to the NOS score criteria and the related meta-analysis was performed. Results: A total of 9 articles were included in the meta-analysis. The results of meta-analysis showed that the effects of TDF and ETV on eGFR, serum creatinine and serum phosphorus were respectively SMD-0.07（95% CI: -0.31~0.16）; -0.15（95% CI: -0.46~0.17）;-0.37(95% CI: -0.66 ~ -0.08). The effects of intergroup on eGFR, serum creatinine and serum phosphorus were respectively(t =2.48,P= 0.056) ;(t= 1.98, P= 0.105);（t=1.41, P=0.252） in the treatment of CHB patients in 24 months. There was a similarity between TDF and ETV for renal safety in patients with CHB. Conclusion: Both TDF and ETV may affect the renal function of the patients with CHB. There may be no significant differences between the effects on eGFR, serum creatinine, serum phosphorus when treated with such two drugs.

参考文献/References:

[1] Najjar Z, Gupta L, Pritchard-Jones J, et al. A survey of Sydney general practitioners’ management of patients with chronic hepa-titis B[J]. Med J Aust, 2016,204:74
[2] Lampertico P, Chan H L, Janssen H L, et al. Review article:long-term safety of nucleoside and nucleotide ana-logues in HBV-monoinfected patients[J]. Aliment Pharmacol Ther, 2016, 44(1):16
[3] Chan H L, Shaikh J, Gupta S, et al. Renal function in nucleos(t) ide analog-treated patients with chronic hepatitis B: a systematic literature review and network meta-analysis[J]. Adv Ther, 2016,33(5): 862
[4] Appel G. Viral infections and the kidney: HIV, hepatitis B, and hepatitis C[J]. Cleve Clin J Med, 2007,74(5):353
[5] Park J, Jung K S,Lee H W, et al. Effects of entecavir and tenofovir on renal function in patients with hepatitis bvirus-related compensated and decompensated cirrhosis[J].Gut Liver, 2017, 11(6):828
[6] Riveiro-Barciela M, Tabernero D, Calleja J L, et al. Effectiveness and safety of entecavir or tenofovir in a Spanish cohort of chronic hepatitis B patients: validation of the page-G score to predict hepatocellular carci-noma[J]. Dig Dis Sci，2017, 62(3):784
[7] Koksal A R, Alkim H, Boga S, et al. Value of cystatin C-based e-GFR measurements topredictlong-term tenofovir nephrotoxicity in patients with hepatitis B[J]. Am J Ther, 2016, 26(1):e25
[8] Tsai M C, Chen C H, Tseng P L, et al. Does nucleos(t)ide analogues treatment affect renal function in chronic hepatitis B patients who have already decreased eGFR? A longitudinal study[J]. PLoS One, 2016, 11(3): e0149761
[9] Tsai M C, Chen C H, Tseng P L, et al. Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience[J]. Clin Microbiol Infect, 2016, 22(1):95
[10] Koklu S, Gulsen M T, Tuna Y, et al. Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B[J]. Aliment Pharmacol Ther, 2015, 41(3):310
[11] Hung C H, Hu T H, Lu S N, et al. Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation[J]. Antimicrob Agents Chemother, 2015, 59(6):3168
[12] Tien C, Xu J J, Chan L S, et al. Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling[J]. Dig Dis Sci, 2015, 60(2):566
[13] No’voa S R, Samaniego J G, et al. Altered underlying renal tubular function in patients with chronic hepatitis B receiving nucleos(t)ide analogs in a real-world setting The mente stud[J].J Clin Gastroenterol, 2016, 50（9）:779
[14] Sarin S K, Kumar M, Lau G K, et al.Asian-pacific clinical practice guidelines on the management of hepatitis B:a2015 update[J].Hepatol Int, 2016,10:1
[15] Sarin S K, Kzowej N H, Chang K, et al. AASLD guidelines for treatment of chronic hepatitis B[J]. Hepatology, 2015,63(1):261
[16] Lampertico P, Vigano M, Yurtaydin C, et al. Effectiveness and safety of tenofovir disoproxil fumarate in field practice: a multicenter European cohort study of 737 patients with chronic hepatitis B[J]. 61th Annual meeting of the American Association for the Study of Liver Diseases(AASLD), October 29-November 2, 2010, Boston, MA
[17] Si-Ahmed S N, Pradat B, Zoutendijk R, et al. Efficacy and tolerance of combin-ation of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study[J]. Antiviral Res ,2011, 92(1):90
[18] Yang Y M, Choi E J. Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection[J]. Ther Clin Risk Manag，2017, 13:1273

相似文献/References:

[1]杨晓玲,李 嘉,周莉,等.恩替卡韦初治代偿期和失代偿期乙肝肝硬化患者96周疗效比较[J].天津医科大学学报,2014,20(03):204.
　YANG Xiao-ling,LI Jia,ZHOU Li,et al.Comparison of entecavir efficacy in initial treatment for HBV patients with compensated and decompensated cirrhosis in 96 weeks[J].Journal of Tianjin Medical University,2014,20(05):204.

备注/Memo

备注/Memo:

作者简介 苏培（1968-），女，主任药师，硕士在读，研究方向：临床药学；通信作者：高卫真， E-mail：Weizhengao 33@163.com。

常用功能

更新日期/Last Update: 2019-10-11